Trailing-twelve-month (TTM) revenue is $31.53 Million with a year-over-year growth of +65.16%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q1 FY2026Period ended 2025-09-30 | $6,680,823 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-13 |
| Q2 FY2026Period ended 2025-12-31 | $7,367,837 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-17 |
| Q3 FY2026Period ended 2026-03-31 | $8,708,631 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-13 |
| Q4 FY2026Period ended 2026-06-30 | $8,774,474 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-09-28 |
| TTM revenue | $31,531,765 |
Current P/S: $49,251,911 market capitalization ÷ $31,531,765 TTM revenue = 1.56x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T20:00:00.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q4 FY2026 (2026-06-30): $8.77M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T20:52:46.439Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2026-06-30 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20212021-06-30 · USD | FY20222022-06-30 · USD | FY20232023-06-30 · USD | FY20242024-06-30 · USD | FY20252025-06-30 · USD | FY20262026-06-30 · USD |
|---|---|---|---|---|---|---|
| Engineering Design Services | $3M | $5M | $7M | $8M | $5M | $3M |
| Medical Device | N/A | $4M | N/A |
$31.53M
$31.53 Million
+65.16%
vs. $19.09M a year ago (TTM)
+24.19%
5 Year compound annual growth rate
1 Year
+65.16%
3 Year
+14.43%
5 Year
+24.19%
10 Year
+23.20%
15 Year
+19.26%
20 Year
+14.02%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2026 | $31.53M | +$12.44M | +65.16% |
| 2025 | $19.09M | ($13,081) | (0.07%) |
| 2024 | $19.10M | ($1.94M) | (9.22%) |
| 2023 | $21.04M | +$5.37M | +34.23% |
| 2022 | $15.68M | +$5.00M | +46.87% |
| 2021 |
TTM Growth
+65.16%
3-Year CAGR
+14.43%
5-Year CAGR
+24.19%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T20:52:46.439Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
| N/A |
| N/A |
| N/A |
| Medical Device Products and Assemblies | $2M | N/A | N/A | N/A | N/A | N/A |
|---|
| Medical Device Products And Assemblies | N/A | N/A | $4M | $2M | N/A | N/A |
|---|
| Optical Components | $6M | $6M | $11M | $8M | N/A | N/A |
|---|
| $10.67M |
| +$751,552 |
| +7.57% |
| 2020 | $9.92M | +$3.12M | +45.84% |
| 2019 | $6.80M | +$2.77M | +68.50% |
| 2018 | $4.04M | +$883,501 | +28.01% |
| 2017 | $3.15M | ($762,155) | (19.46%) |
